Developing new treatments for glioblastoma that resist standard therapies
Perivascular tissue models to overcome MGMT-mediated temozolomide resistance in glioblastoma
['FUNDING_R01'] · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · NIH-10991012
This study is looking at glioblastoma, a tough brain cancer that often doesn't respond well to a common treatment, and aims to create special lab models to better understand how the cancer spreads and to test new drugs that might work better for patients like you.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN (nih funded) |
| Locations | 1 site (CHAMPAIGN, UNITED STATES) |
| Trial ID | NIH-10991012 on ClinicalTrials.gov |
What this research studies
This research focuses on glioblastoma, a highly aggressive brain cancer that often resists treatment with the drug temozolomide due to a protein called MGMT. The team aims to create advanced tissue models that mimic the tumor environment to better understand how glioblastoma invades surrounding tissues and to test new drug derivatives that could bypass MGMT resistance. By using innovative biomaterials and microfluidics technology, they will develop and evaluate these new treatment options in a controlled laboratory setting. This approach could lead to more effective therapies for patients with this challenging cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who have shown resistance to temozolomide treatment.
Not a fit: Patients with glioblastoma who are not resistant to temozolomide or those with other types of brain tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for glioblastoma patients who currently have limited effective therapies.
How similar studies have performed: While the approach of using engineered tissue models is innovative, similar strategies have shown promise in other cancer research, indicating potential for success.
Where this research is happening
CHAMPAIGN, UNITED STATES
- UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN — CHAMPAIGN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HARLEY, BRENDAN A. — UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN
- Study coordinator: HARLEY, BRENDAN A.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer